Is SRBCF or JNJ a better dividend investment in 2026?

SRBCF currently yields 39215.69% with a 5% 5-year dividend growth rate. JNJ yields 2.13% with 5.8% growth. The better choice depends on your goal: SRBCF offers higher current income.

What is the dividend yield difference between SRBCF and JNJ?

SRBCF has a forward dividend yield of 39215.69% ($2.00/share annually). JNJ yields 2.13% ($5.20/share annually). The yield gap is 39213.56 percentage points.

Home › Compare › SRBCF vs JNJ

SRBCF vs JNJ: Dividend Comparison 2026

SRBCF yields 39215.69% · JNJ yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SRBCF wins by $4.252735580217355e+22M in total portfolio value

INVESTMENT

TIME HORIZON10 years

SRBCF

● Live price

39215.69%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.252735580217355e+22M

Annual income

$42,315,093,309,418,040,000,000,000,000.00

Full SRBCF calculator →

JNJ

Johnson & Johnson

● Live price

2.13%

Share price

$244.44

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.3K

Annual income

$4,689.40

Full JNJ calculator →

Portfolio growth — SRBCF vs JNJ

📍 SRBCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SRBCF	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SRBCF + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SRBCF pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRBCF

Annual income on $10K today (after 15% tax)

$3,333,333.33/yr

After 10yr DRIP, annual income (after tax)

$35,967,829,313,005,333,000,000,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$180.82/yr

After 10yr DRIP, annual income (after tax)

$3,985.99/yr

At 15% tax rate, SRBCF beats the other by $35,967,829,313,005,333,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRBCF + JNJ for your $10,000?

SRBCF: 50%JNJ: 50%

100% JNJ50/50100% SRBCF

Portfolio after 10yr

$2.1263677901086776e+22M

Annual income

$21,157,546,654,709,020,000,000,000,000.00/yr

Blended yield

99.50%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SRBCF

No analyst data

Altman Z

-90.9

Piotroski

2/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-6.4% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRBCF buys

JNJ buys

No recent congressional trades found for SRBCF or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSRBCFJNJ

Forward yield	39215.69% ✓	2.13%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$4.252735580217355e+22M	$30.3K ✓
Annual income after 10y	$42,315,093,309,418,040,000,000,000,000.00 ✓	$4,689.40
Total dividends collected	$4.251340866571809e+22M	$15.4K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: SRBCF vs JNJ ($10,000, DRIP)

Year	SRBCF Portfolio	SRBCF Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$3,932,269	$3,921,568.63	$10,592	$272.30	+$3.92M → SRBCF
2	$1,445,390,825	$1,441,183,297.58	$11,289	$357.73	+$1445.38M → SRBCF
3	$496,629,048,205	$495,082,480,022.34	$12,123	$472.89	+$496629.04M → SRBCF
4	$159,510,701,964,776	$158,979,308,883,196.16	$13,141	$629.86	+$159510701.95M → SRBCF
5	$47,892,225,784,148,210	$47,721,549,333,045,900.00	$14,408	$846.81	+$47892225784.13M → SRBCF
6	$13,442,027,069,357,296,000	$13,390,782,387,768,257,000.00	$16,021	$1,151.60	+$13442027069357.28M → SRBCF
7	$3,526,928,149,355,307,700,000	$3,512,545,180,391,095,400,000.00	$18,122	$1,588.22	+$3526928149355307.50M → SRBCF
8	$865,104,634,553,737,800,000,000	$861,330,821,433,927,700,000,000.00	$20,930	$2,228.20	+$865104634553737856.00M → SRBCF
9	$198,376,161,453,751,100,000,000,000	$197,450,499,494,778,630,000,000,000.00	$24,792	$3,191.91	+$198376161453751107584.00M → SRBCF
10	$42,527,355,802,173,560,000,000,000,000	$42,315,093,309,418,040,000,000,000,000.00	$30,274	$4,689.40	+$4.252735580217355e+22M → SRBCF

SRBCF vs JNJ: Complete Analysis 2026

SRBCF — Stock

Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. Its programs include cosmetic skin lightener and diabetes drug; and other projects include the development of an anti-aging/cell protection library, novel anti-wrinkle compound, and anti-viral program. Sirona Biochem Corp. has a research collaboration agreement with the International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop antiviral library of compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.

Full SRBCF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this SRBCF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRBCF vs SCHD SRBCF vs JEPI SRBCF vs O SRBCF vs KO SRBCF vs MAIN SRBCF vs ABBV SRBCF vs MRK SRBCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.